Clinical Report: Real-World Management and Outcomes of Lupus Nephritis
Overview
This study examines the management and outcomes of lupus nephritis (LN) in a cohort of 66 patients. The findings indicate a high rate of non-response to treatment across different LN classes.
Background
Lupus nephritis is a severe manifestation of systemic lupus erythematosus (SLE), affecting a substantial proportion of patients. This study aims to provide insights into treatment responses and complications in a clinical setting.
Data Highlights
Parameter
Class I & II
Class III
Class IV
Class V
No Response at 6 Months
50%
49%
49%
83%
No Response at 12 Months
55%
50%
50%
87%
ESRD Advancement
11 patients (17%)
Infections Requiring Hospital Admission
27 patients (41%)
Death
9 patients (14%)
Key Findings
66 patients with biopsy-proven lupus nephritis were analyzed.
Median age at biopsy was 35 years, with 76% being women and 62% African American.
At 6 months, 50% of Class I and II, 49% of Class III, IV, and III + V, and 83% of Class V LN patients had no response to treatment.
At 12 months, 55% of Class I and II, 50% of Class III, IV, and III + V, and 87% of Class V LN patients had no response, with a significant difference noted (p = 0.04).
Complications included 11 patients (17%) advancing to end-stage renal disease (ESRD) and 27 patients (41%) experiencing infections requiring hospitalization.
9 patients (14%) died during the study period.
Clinical Implications
The study highlights the need for individualized treatment approaches and the importance of addressing socioeconomic factors in managing lupus nephritis. Early biopsy and prompt treatment initiation are crucial for improving patient outcomes.
Conclusion
This study provides data on lupus nephritis management and the challenges faced in treatment.
